Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicholas Cannarozzi

Rheumatology West Orange, NJ Medical Doctor

NPI 1194810259 CMS profile 8451

741 Northfield Ave, Suite 210, West Orange, NJ 07052

Open in the dashboard

General payments

$6,368

461 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicholas Cannarozzi of West Orange, NJ is reported in the CMS Open Payments database as having received $6,368 across 461 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,085 68
2024 General $1,365 87
2023 General $831 59
2022 General $619 51
2021 General $272 20
2020 General $370 26
2019 General $1,827 150

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Cannarozzi
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Nicholas Cannarozzi were reported at $1,085. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Nicholas Cannarozzi Rheumatology median Middle half National median
2019 $1,827 $744 $153–$2,687 $163
2020 $370 $462 $98–$2,027 $114
2021 $272 $531 $101–$2,153 $132
2022 $619 $627 $125–$2,303 $149
2023 $831 $741 $145–$2,524 $160
2024 $1,365 $830 $166–$2,660 $164
2025 $1,085 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,142 85 payments
  2. Novartis Pharmaceuticals Corporation $993 70 payments
  3. Pfizer Inc. $984 76 payments
  4. AbbVie, Inc. $733 51 payments
  5. Janssen Biotech, Inc. $394 27 payments
  6. E.R. Squibb & Sons, L.L.C. $332 26 payments
  7. Genentech USA, Inc. $321 29 payments
  8. UCB, Inc. $272 17 payments
  9. Lilly USA, LLC $270 19 payments
  10. Genzyme Corporation $149 10 payments
  11. Other $780 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,225 457 payments
  2. Education $143 4 payments
Products named General payments · program years 2019–2025
  1. XELJANZ $957 74 payments
  2. COSENTYX Dermatology $469 35 payments
  3. RINVOQ $385 27 payments
  4. Prolia $373 28 payments
  5. ORENCIA $318 25 payments
  6. Actemra $317 28 payments
  7. EVENITY $299 20 payments
  8. TALTZ $257 18 payments
  9. ILARIS $242 13 payments
  10. COSENTYX Immunology $237 15 payments
  11. Other $3,192 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

599

Median for Rheumatology: 1,511

Drug cost

$560,396

Median for Rheumatology: $1,139,948

Branded share of claims

43.2%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Etanercept Brand 43 $259,421
Humira(Cf) Pen Adalimumab Brand 19 $128,010
Simponi Golimumab Brand 14 $82,818
Orencia Clickject Abatacept Brand 12 $79,363
Methotrexate Methotrexate Sodium Brand 171 $3,702
Hydroxychloroquine Sulfate Generic 52 $2,046
Duloxetine Hcl Generic 25 $705
Celecoxib Generic 36 $677
Pregabalin Generic 16 $674
Alendronate Sodium Generic 47 $625

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$15,505

Medicare's payments for the services billed

Medicare patients

72

Average age 74

Services billed

278

47 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 46%
Diabetes 32%
Ischemic heart disease 21%
Chronic kidney disease 19%
Heart failure 18%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XELJANZ
  • PFIZER INC. $251
$251 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $143
$143 — —
Enbrel
  • Amgen Inc. $97
$97 43 —
TREMFYA
  • Janssen Biotech, Inc. $84
$84 — —
RINVOQ
  • AbbVie, Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

461 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record